KING KRISTINA

No ORCID on file · 154 papers in corpus
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
2010
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY